Blue water vaccines announces plans to evaluate efficacy of streptococcus pneumoniae vaccine candidate against pneumococcal pneumonia at the world vaccine congress in barcelona

Cincinnati, oct. 11, 2022 (globe newswire) -- blue water vaccines inc. (“bwv” or “blue water vaccines” or the “company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced plans to investigate the ability of bwv-201, a streptococcus pneumoniae vaccine candidate for acute otitis media (“aom”) prevention, to also protect against non-invasive pneumococcal pneumonia at the world vaccine congress in barcelona.
BWV Ratings Summary
BWV Quant Ranking